Latest Ratios: P/E Ratio 7.4x · EV/EBITDA 4.1x · ROE 22.6%. (2010–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $1.2B | $1.1B | $162M | $119M | $1.2B | — | — | — | — | — | — |
| Enterprise Value | $1.4B | $1.3B | $458M | $373M | $1.4B | — | — | — | — | — | — |
| P/E Ratio → | 7.39 | 15.71 | 3.26 | — | — | — | — | — | — | — | — |
| P/S Ratio | 1.49 | 1.27 | 0.34 | 0.48 | 5.50 | — | — | — | — | — | — |
| P/B Ratio | 2.76 | 2.63 | 0.80 | 1.50 | 10.02 | — | — | — | — | — | — |
| P/FCF | 4.72 | 4.53 | 7.75 | — | 33.53 | — | — | — | — | — | — |
| P/OCF | 4.79 | 4.48 | 6.98 | 94.73 | 23.84 | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 1.46 | 0.95 | 1.51 | 6.56 | — | — | — | — | — | — |
| EV / EBITDA | 4.07 | 4.32 | 3.06 | — | — | — | — | — | — | — | — |
| EV / EBIT | 4.91 | 4.79 | 3.53 | — | — | — | — | — | — | — | — |
| EV / FCF | — | 5.20 | 21.98 | — | 40.01 | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 50.8% | 50.8% | 40.9% | 14.0% | 7.0% | 54.1% | 57.5% | 58.6% | 62.8% | -2336.2% | — |
| Operating Margin | 31.5% | 31.5% | 27.2% | -12.8% | -185.4% | 51.4% | 55.9% | 35.8% | -61.5% | -10165.0% | — |
| Net Profit Margin | 8.1% | 8.1% | 10.9% | -18.5% | -193.7% | 40.0% | 38.7% | 21.6% | -205.9% | 2512.6% | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 22.6% | 22.6% | 37.1% | -45.9% | -272.4% | 78.2% | 106.9% | 84.8% | -645.7% | 24.6% | — |
| ROA | 9.0% | 9.0% | 9.9% | -11.0% | -102.8% | 37.7% | 43.4% | 23.3% | -149.0% | 30.3% | -182.4% |
| ROIC | 38.0% | 38.0% | 23.6% | -6.9% | -88.7% | 42.1% | 52.8% | 32.0% | -50.2% | — | — |
| ROCE | 43.2% | 43.2% | 30.6% | -8.9% | -110.8% | 53.7% | 79.7% | 65.2% | -94.7% | -99.4% | — |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.83 | 0.83 | 1.69 | 3.49 | 2.22 | 0.93 | 1.02 | 2.36 | — | 0.16 | — |
| Debt / EBITDA | 1.19 | 1.19 | 2.27 | — | — | 1.00 | 0.94 | 3.23 | — | — | — |
| Net Debt / Equity | — | 0.39 | 1.47 | 3.21 | 1.94 | 0.74 | 0.85 | 2.20 | — | 0.16 | — |
| Net Debt / EBITDA | 0.56 | 0.56 | 1.98 | — | — | 0.80 | 0.78 | 3.01 | — | — | — |
| Debt / FCF | — | 0.68 | 14.23 | — | 6.48 | 1.04 | 4.89 | — | — | — | — |
| Interest Coverage | 12.01 | 12.01 | 6.51 | -1.97 | -32.60 | 28.35 | 23.66 | 10.09 | -7.65 | -15.35 | -173.90 |
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 3.41 | 3.41 | 2.08 | 1.56 | 1.79 | 4.09 | 4.31 | 0.63 | 0.29 | 0.06 | 0.08 |
| Quick Ratio | 3.39 | 3.39 | 2.06 | 1.50 | 1.72 | 4.01 | 4.25 | 0.62 | 0.27 | 0.06 | 0.08 |
| Cash Ratio | 1.18 | 1.18 | 0.31 | 0.38 | 0.62 | 0.96 | 0.81 | 0.11 | 0.11 | 0.01 | 0.00 |
| Asset Turnover | — | 0.95 | 0.73 | 0.62 | 0.51 | 0.84 | 0.89 | 0.54 | 3.04 | 0.01 | — |
| Inventory Turnover | 150.38 | 150.38 | 99.55 | 62.78 | 57.70 | 54.10 | 67.46 | 44.63 | 18.77 | — | — |
| Days Sales Outstanding | — | 135.71 | 179.52 | 92.52 | 97.06 | 126.34 | 144.04 | 135.91 | 49.70 | 98.54 | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | 6.4% | 6.7% | 4.0% | 4.4% | 4.2% | — | — | — | — | — | — |
| Payout Ratio | 104.9% | 104.9% | 12.3% | — | — | 108.9% | 55.7% | 90.3% | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | 13.5% | 6.4% | 30.6% | — | — | — | — | — | — | — | — |
| FCF Yield | 21.2% | 22.1% | 12.9% | — | 3.0% | — | — | — | — | — | — |
| Buyback Yield | 0.4% | 0.4% | 0.0% | 0.0% | 0.0% | — | — | — | — | — | — |
| Total Shareholder Yield | 6.8% | 7.1% | 4.0% | 4.4% | 4.2% | — | — | — | — | — | — |
| Shares Outstanding | — | $7M | $5M | $4M | $4M | $4M | $4M | $4M | $7M | $4M | $2M |
Includes 30+ ratios · 13 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying NUTX stock.
Nutex Health, Inc.'s current P/E ratio is 7.4x. The historical average is 9.5x. This places it at the 50th percentile of its historical range.
Nutex Health, Inc.'s current EV/EBITDA is 4.1x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 3.7x.
Nutex Health, Inc.'s return on equity (ROE) is 22.6%. This is above the typical threshold of 15-20% considered good for most companies. The historical average is 2.5%.
Based on historical data, Nutex Health, Inc. is trading at a P/E of 7.4x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Nutex Health, Inc.'s current dividend yield is 6.36% with a payout ratio of 104.9%.
Nutex Health, Inc. has 50.8% gross margin and 31.5% operating margin. Operating margin above 20% indicates strong pricing power and cost efficiency.
Nutex Health, Inc.'s Debt/EBITDA ratio is 1.2x, indicating moderate leverage. A ratio below 2x is generally considered financially healthy.
Key Metrics
Top Statement Risk
Earnings quality and cash volatility
Metrics are mathematically derived from official filings.
Discounted Multiples Reflect Earnings Skepticism
Based on Nutex's reported figures, the trailing P/E of 7.42 and EV/EBITDA of 4.09 sit well below the 20.57 P/E and 14.12 EV/EBITDA of peer Addus HomeCare, suggesting the market is pricing in durability doubts about recent profits.
The forward P/E of 6.35 sits below the trailing multiple, which implies the market expects earnings to hold or grow despite the recent year-over-year revenue decline of 18.7%. The 6.3% dividend yield and 4.74 P/FCF multiple suggest investors are being compensated for volatility, though whether the discount reflects a mispricing or a rational response to lumpy cash generation warrants further investigation.
Operating Margins Outrun Net Earnings Power
According to reported quarterly figures, Nutex's operating margin of 35.4% in 2026Q3 compares with a net margin of 18.5%, a gap that appears driven by below-the-line items rather than core operations.
Operating margin swung from 13.8% to 57.8% across recent quarters, indicating that headline profitability is highly sensitive to volume and cost timing rather than a stable structural level. The persistent gap between operating and net margin suggests interest, amortization, or other non-operating charges may be absorbing a meaningful share of earnings, and investors should monitor whether this drag narrows as the network scales.
Returns Oscillate Without Clear Compounding
Based on reported figures, ROIC moved from 1.2% in 2024Q2 to 20.5% in 2024Q4 and 8.9% in 2026Q3, a pattern that suggests returns are episodic rather than compounding.
The trajectory indicates that return on invested capital is driven more by margin spikes than by consistent asset efficiency, given asset turnover of roughly 0.2 across quarters. Compared with peer AMERISAFE's 21.9% ROIC, Nutex's current 8.9% appears modest, implying the capital base may not yet be generating returns commensurate with its facility footprint.
Leverage Easing as Equity Rebuilds
As reported in financial statements, Nutex's debt-to-equity ratio fell from 3.80 in 2024Q3 to 0.67 in 2026Q3, while interest coverage strengthened to 15.92x, indicating debt service has become considerably more comfortable.
Absolute debt has remained broadly flat near $340M to $390M, so the improvement in leverage ratios appears to be driven primarily by equity growth rather than debt reduction. Net debt to EBITDA of 4.41 remains elevated in absolute terms, and refinancing exposure cannot be assessed from the provided data alone.
Cash Buffer Strong but Quarterly Swings
Based on Nutex's reported figures, a current ratio of 4.76 and cash of $249.9M in 2026Q3 indicate ample short-term coverage, though cash has ranged from $40.8M to $249.9M across the ten quarters.
The quick ratio of 4.72 is nearly identical to the current ratio, which suggests inventory is negligible and liquidity depends on receivables and cash rather than physical stock. Because working capital timing dominates quarterly cash flow, the liquidity position may look far weaker under a period of slowed collections, which warrants monitoring.
Headline Margins Mask Earnings Volatility
Based on reported quarterly figures, Nutex's 2026Q3 operating margin of 35.4% and ROIC of 8.9% may overstate durable earning power, given swings from 13.8% to 57.8% in operating margin over recent quarters.
The most commonly misapplied ratio for a micro-hospital operator is the headline operating margin, which captures fixed-cost leverage at a single point in a volatile volume cycle rather than normalized earning power. Investors should instead anchor on trailing multi-quarter averages of operating margin and free cash flow after working capital changes, which better reflect the reimbursement and collection timing that drives quarterly results.